| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5693017 | European Urology | 2017 | 12 Pages |
Abstract
Low-risk prostate cancer is very common. Active surveillance has excellent long-term results, while randomized trials have failed to show a beneficial impact of immediate radical treatments on survival. Biomarkers and magnetic resonance imaging may help to identify which men may benefit from early treatment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Marco Moschini, Peter R. Carroll, Scott E. Eggener, Jonathan I. Epstein, Markus Graefen, Rodolfo Montironi, Christopher Parker,